Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

Presently there is only one approved drug, venetoclax, that takes advantage of CLL’s dependence on turning off the cancer cell’s death cycle. But others are in trials which augurs well for chronic lymphocytic leukemia patients if they prove to be as good a CLL killer as venetoclax.

APG-2575 is a novel molecule that inhibits Bcl-2 as does venetoclax and is now being studied in Europe. For more information, read the press release from Ascentage Pharma here.

CLL Society believes the more treatment options that we patients have, the better.

Stay strong, we are all in this together.

Brian Koffman
Executive Vice-President and Chief Medical Officer, CLL Society

For more details see the official press release.